Psychedelic Health

03/01/2024

Doctors have raised a warning against so-called “trip killers” that are used to end challenging psychedelic experiences on compounds such as L*D or psilocybin.

20/12/2023

Want to understand more about in ?

Psychedelics Today has produced a new report that aims to understand more about the emerging workforce, diversity in the industry and the need for a knowledgeable workforce of people.

Director of Education David Drapkin LCSW tells us more. 👇

Psychedelics Today recently surveyed students and graduates of its 12-month intensive professional psychedelic certification programme, Vital, publishing its findings in The Emerging Psychedelic Workforce report.

12/12/2023

A new company specialising in psychedelic medicine - mychedelica - is offering a comprehensive suite of services to support the advancement of this transformative field.

12/12/2023

The first-ever psilocybin trial for treatment-resistant bipolar type II disorder has shown 80% of participants meeting remission criteria 12 weeks after treatment.

Find out more. 👇

The first-ever psilocybin trial for treatment-resistant bipolar type II disorder has shown 80% of participants meeting remission criteria 12 weeks after treatment.

05/12/2023

A new study has mapped the effects of ketamine on the , finding that repeated use over extended periods creates widespread structural changes in the brain’s system.

Find out more. 👇

A new study has mapped the effects of ketamine on the brain, finding that repeated use over extended periods creates widespread structural changes in the brain’s dopamine system.

01/12/2023

Mindbloom has launched its new Mastermind Series of psychedelic programmes for overcoming heartbreak, burnout and other unique mental health challenges.

Find out more. 👇

Mindbloom has launched its new Mastermind Series of psychedelic programmes for overcoming heartbreak, burnout and other unique mental health challenges.

30/11/2023

Positive Phase 2 topline safety and efficacy data CybinInc's psilocybin analogue – CYB003 – for the treatment of major depressive disorder has shown 79% of patients were in remission from at six weeks after two doses.

Cybin CMO, Amir Inamdar MBBS, DNB (Psych), MFPM, stated: “With these findings in hand, we are encouraged by the potential of CYB003 to help those with MDD and look forward to progressing to a multinational, multisite Phase 3 study early next year.”

Cybin has announced positive Phase 2 topline safety and efficacy data for its proprietary deuterated psilocybin analogue - CYB003 - for the treatment of major depressive disorder (MDD).

29/11/2023

Ketamine is an FDA-approved medical anesthetic and recently, a prescription nasal spray version of ketamine called esketamine was approved for treatment-resistant depression.

Find out more about what a k-hole is, the half-life of ketamine and what signs to look out for in case of a ketamine overdose. 👇

Ketamine is an FDA-approved medical anesthetic and recently a prescription nasal spray version of ketamine called esketamine (Spravato) was approved for treatment-resistant depression.

28/11/2023

mychedelica has launched to offer a comprehensive suite of services to support the advancement of .

CEO of mychedelica, Bilal Bham, commented: “Our team of experienced professionals is dedicated to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in this groundbreaking field.”

Find out more. 👇

A new company specialising in psychedelic medicine - mychedelica - is offering a comprehensive suite of services to support the advancement of this transformative field.

27/11/2023

Clerkenwell Health is calling for volunteers to join its groundbreaking that will research whether psychedelics can provide effective treatments for complex conditions.

Chief Scientific Officer at Clerkenwell Health, Dr Henry Fisher, said: “By participating in upcoming clinical trials, patients have an opportunity to make a valuable contribution to growing research which will support the development of the next generation treatments for mental health conditions.”

Find out more. 👇

Mental health research provider Clerkenwell Health is calling for volunteers to join its groundbreaking clinical trials that will research whether psychedelics can provide effective treatments for complex mental health conditions.

24/11/2023

We speak to Short Wave Pharma CEO Rivki Stern Youdkevich about the company’s plans to innovate care through and its recent acquisition by Psych Capital.

“We have a shared commitment to alleviate the suffering from mental health. Every one of us has experienced the frustration and challenges of dealing with mental health issues," says Stern.

“Together, we’re going to put this commitment into action, by bringing forth innovative solutions and developments and getting them through the first stages of development, from discovery through to early phases of clinical study."

Find out more. 👇

Psychedelic Health speaks to Short Wave Pharma CEO Rivki Stern about the company’s plans to innovate eating disorder care through psychedelics and its recent acquisition by Psych Capital.

23/11/2023

Clearmind Medicine has announced receipt of a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq. The company now plans to appeal the Staff’s determination to a Hearings Panel.

Find out more. 👇

Biotech company Clearmind Medicine has announced receipt of a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq.

22/11/2023

A new paper has explored the extended difficulties experienced by some people following psychedelic drug use and discusses psychedelic .

Find out more. 👇

A new paper has explored the extended difficulties experienced by some people following psychedelic drug use and discusses psychedelic harm reduction.

21/11/2023

Activists in Oakland recently filed a ballot put forward by Dave Hodges seeking to legalise safe and legal access to psychedelics for therapeutic uses.

In the face of critics, Hodges has said now is the time for safe access to .

👇

Activists in Oakland recently filed a ballot put forward by Dave Hodges seeking to legalise safe and legal access to psychedelics for therapeutic uses.

20/11/2023

Compass Pathways has confirmed that the UK component of its Phase 3 trial investigating psilocybin for treatment-resistant depression has now launched.

CEO of Compass Pathways, Kabir Nath, commented: “The launch of our Phase 3 clinical study in treatment-resistant depression here in the UK is an important step in developing innovations that are urgently needed, and we recognise the important role that public-private partnerships play in this.”

Compass Pathways has confirmed that the UK component of its Phase 3 trial investigating psilocybin for treatment-resistant depression has now launched.

17/11/2023

A groundbreaking observational study is set to investigate the real-world efficacy of M**A-assisted therapy through Health Canada’s Special Access Programme.

PharmAla Biotech, the University of Calgary and Heroic Hearts Project Canada – a non-profit organisation that supports Veteran access to psychedelic therapies – are partnering to carry out the trial.

Find out more. 👇

A groundbreaking observational study is set to investigate the real-world efficacy of M**A-assisted therapy through Health Canada’s Special Access Programme (SAP).

16/11/2023

A new report has been released by Canada’s Senate Subcommittee on Veterans Affairs – ‘The Time Is Now: Granting Equitable Access to Psychedelic Assisted Therapies’ – which recommends the launch of a large-scale research programme on psychedelics for Veterans’ mental health.

Jay Katz, Executive Director of the Psychedelic Association of Canada, welcomed the recommendation, stating: “The PAC is encouraged by the contents of the Senate Subcommittee’s report. Their acknowledgement of the potential inherent in reshaping our approach to treating mental illness is an auspicious first step. It paves the way for significantly improved outcomes.”

A new report has been released by Canada's Senate Subcommittee on Veterans Affairs - ‘The Time Is Now: Granting Equitable Access to Psychedelic Assisted Therapies’ - which recommends the launch of a large-scale research programme on psychedelics for Veternas’ mental health.

15/11/2023

Transform Drug Policy Foundation has published a new book ‘How to Regulate Psychedelics: A Practical Guide’ that sets out how can be legalised and regulated for non-medical adult use.

Co-author and Public Affairs and Policy Manager at Transform Drug Policy Foundation, Ester Kincová, stated: “Legalising and regulating psychedelics is a pragmatic move to reduce harm. This is no longer a theoretical debate, states in the US are already recognising the need and making moves to regulate for non-medical adult use.”

UK charity Transform Drug Policy Foundation has published a new book ‘How to Regulate Psychedelics: A Practical Guide’ that sets out how psychedelics can be legalised and regulated for non-medical adult use.